Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Robbins LLPRobbins LLP Reminds REGN Stockholders of the Pending Lead Plaintiff Deadline in the Class Action Against Regeneron Pharmaceuticals, Inc.Robbins LLP reminds investors that a securities class action has been filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between August 1, 2025 and May 15, 2026, inclusive (the "Class Period").The lawsuit alleges that Regeneron Pharmaceuticals misled investors regarding the viability and prospects of its Phase 3 Fianlimab-Libtayo clinical trial for patients with...
- Mauna Kea Technologies Announces Publication of a Landmark Systematic Review and Meta-Analysis Reinforcing the Diagnostic Accuracy and Clinical Impact of Cellvizio in Upper Gastrointestinal CancerPARIS & BOSTON, August 26, 2026--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the publication of a landmark independent systematic review and meta-analysis of probe-based confocal laser endomicroscopy (pCLE) in upper gastrointestinal cancer, conducted and funded by Korea's national health technology assessment agency.
- Anthem Blue Cross and Blue Shield Foundation Launches Impact Investment Fund to Strengthen Ohio CommunitiesCOLUMBUS, Ohio, August 26, 2026--The Anthem Blue Cross and Blue Shield Foundation, the charitable arm of Anthem Blue Cross and Blue Shield, launched a new program that deploys capital into mission-driven organizations working to improve health-related social needs.
- Cizzle BioCizzle Bio Highlights CIZ1B Biomarker Blood Test for Lung Cancer at Next Generation Dx SummitMoffitt Cancer Center's Dr. Lary Robinson discusses blood-based biomarkers in early lung cancer detection and ongoing CIZ1B clinical study — Cizzle Bio Inc., a biotechnology company advancing biomarker blood tests for early cancer detection, today...
- Thyme CareThyme Care Earns NCQA Accreditation for Both Its Cancer Case Management and Population Health ProgramsNCQA evaluated Thyme Care's cancer programs against two separate sets of national standards, covering care planning and monitoring, data integration, staff licensure and training. — Thyme Care, the oncology company aligning accountability...
- China State Construction International Delivers Significant Results in Low-Carbon ConstructionChina State Construction International Holdings Limited (“China State Construction International” or the “Group”, stock code: 03311), a pioneer in construction industrialisation, has continued to deepen its deployment of technologies including Modular Integrated Construction (“MiC”), Multi-trade Integrated Mechanical, Electrical and Plumbing (“MiMEP”) and Building-integrated Photovoltaics (“BIPV”). As governments in different markets accelerate the development of green buildings, ultra-low energy buildings and new construction industrialisation, demand for efficient and low-carbon construction solutions continues to grow. These businesses have become an important pillar supporting the Group’s transformation towards smart construction. Policy Support and Market Demand Drive Green Construction The construction industry is facing multiple requirements to improve energy efficiency, reduce carbon emissions and minimise construction waste. The Chinese Mainland’s 15th Five-Year Plan promotes coordinated progress in carbon reduction, pollution control, green expansion and economic growth, and proposes the wider adoption of green and low-carbon construction methods, as well as the scaled development of ultra-low-energy buildings and prefabricated buildings. Relevant action plans for the construction sector also encourage the advancement of building-integrated photovoltaics, greater use of renewable energy and stronger efforts to enhance building energy conservation and carbon reduction. Hong Kong’s Climate Action Plan 2050 promotes energy-saving green buildings and waste reduction, with the target of achieving carbon neutrality before 2050 while progressively reducing building energy consumption and reliance on landfills. The Group’s subsidiary, China State Construction Hailong, has continued to promote the scaled application of MiC technology. Data show that carbon emissions during the construction phase of concrete MiC and steel-structure MiC can be reduced by 66.78% and 49.61%, respectively. Compared with traditional construction methods, construction waste can be reduced by more than 75%, material wastage by more than 25%, site electricity consumption by 60% and water consumption by 66%. Over the past five years, the Group has supplied more than 129,155 MiC modules across 116 projects, fully demonstrating the replicability of its technological achievements and its capability for large-scale implementation. Benchmark Projects Demonstrate Technological Advantages In Hong Kong, the Chinese Medicine Hospital of Hong Kong and the Government Chinese Medicines Testing Institute project is the city’s first permanent hospital to adopt MiC and MiMEP. The Group designed and produced more than 7,000 MiMEP prefabricated modules for the project, compressing the mechanical, electrical and plumbing construction cycle from the traditional two to three years to within six months, shortening the construction period by more than 75%. Compared with conventional construction methods, the project reduced carbon dioxide emissions by approximately 1,596 tonnes, representing a carbon reduction of 43%. In addition, the IL9088 New Central Harbourfront Development Project applies approximately 2,500 MiMEP modules. Through standardised and interchangeable design, the project enhances construction efficiency for a high-end commercial complex and provides flexibility for future tenant changes and spatial reconfiguration, thereby reducing repeated construction works and renovation waste. In Shenzhen, the Huazhang New Affordable Housing Project, a development in which the Group participated, successfully passed the 2025 ultra-low-energy building review and became the only residential development among Shenzhen’s first batch of pilot projects. The project comprises five residential towers and 6,028 concrete modules, integrating standardised, industrialised, digitalised, intelligent and green solutions. It was completed and delivered within 365 days, providing 2,740 units of government-subsidised rental housing. In Guangzhou, the Dachong Resettlement Housing Project in Nansha District became China’s first modular building project to receive a 6% floor area ratio incentive in 2025, reflecting the effective integration of the Group’s MiC technology with local policies and public housing needs. ESG Performance Continues to Receive Market Recognition With the practical application of low-carbon technologies and quantifiable results, the Group’s MSCI ESG rating was upgraded from BBB to A, representing a three-notch improvement within two years. The Group has also been selected as a constituent of the FTSE4Good Index Series for 10 consecutive years and included in S&P Global Sustainability Yearbook (China Edition) for four consecutive years, reflecting the capital markets’ recognition of the Group’s green transformation strategy and long-term sustainable development capabilities. China State Construction International will continue to leverage its integrated “Technology + Investment + Construction + Asset Operation” strategy, and capitalise on its technological strengths in MiC, MiMEP and BIPV. The Group will further expand the large-scale application of green construction solutions and explore green finance and green asset operation models, creating long-term value for shareholders, investors and society with both environmental benefits and financial returns.
- Kaplan Fox & Kilsheimer LLPKaplan Fox & Kilsheimer LLP is Investigating Hims & Hers Health, Inc. (HIMS) for Possible Securities Law ViolationsKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing...
- Scene Health Appoints Lisa Ritsky-Lamb as Chief Financial Officer to Accelerate Next Phase of GrowthScene Health Appoints Lisa Ritsky-Lamb as Chief Financial Officer
- Flo Health’s GDPR Compliance and Privacy, Security Protections Stand Up to Independent ISO ScrutinyLONDON, August 26, 2026--Flo Health, the #1 female health app used by more than 300 million people worldwide, has completed its annual ISO 27001 and ISO 27701 audits, which returned zero findings. This means independent auditors identified no areas for improvement in the company's privacy and security management systems.
- ViiV HealthcareU.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young childrenLONDON, August 26, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir (DTG)), for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in paediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor (INSTI)-naïve) weighing at least 2 kg.
- Berger MontagueBerger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS)National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and made...
- NeOnc’s Clinical Story Is Now the Main EventNeOnc’s (NASDAQ: NTHI) Clinical Story Is Now the Main Event